Investing in Valeant Pharmaceuticals Intl Inc. Requires Immense Patience

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) got its short-term debt under control, but in a few years, it could become a problem again. Will the pipeline save the company?

| More on:
calm, no emotion

In a market environment like we have now, where it really only looks like things are going up and to the right, it can be difficult to have patience.

However, for investors that have their eye on Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), patience is going to be everything. This company still has a long way to go before it achieves a stock price like it once had.

The problem with Valeant comes down to its debt. Management has been fighting aggressively to try to get Valeant’s debt under control. Valeant’s original business model of buying products and then hiking the price is no longer an acceptable approach.

So, Valeant started selling assets left and right. Management put in place a strategy to pay down US$5 billion by February 2018. It has already paid back more than US$4.8 billion, and it is expected to surpass the original US$5 billion goal.

Nevertheless, Valeant still sits on a lot of debt, which concerns people. However, there is a bright side to its debt. On August 15, Valeant redeemed the remaining US$500 million owed on its outstanding 6.75% senior notes due 2018.

This point is important because it gives Valeant runway. Between now and 2020, it has no debt maturation. In 2020, Valeant will have to pay US$5.8 billion with an additional US$10.5 billion due by 2022. While the future remains quite dire, there’s time, and that’s what management has been fighting for.

In its Q2 2016 results, a few things jumped out at me that make me excited. The first is that Bausch+Lomb/International had revenue of US$1.24 billion, which was up 6% from Q2 2016.

And Salix, which was one of the company’s last acquisitions, had 16% growth in revenue. This actually prevented a drop in revenue in Valeant’s Branded Rx division, which had US$636 million in revenue, basically unchanged.

The full-year 2017 revenue guidance has remained relatively consistent. Originally, management projected US$8.9-9.1 billion in revenue, but that dropped to US$8.7-8.9 billion because of the US$811 million sale of Dendreon Pharmaceuticals LLC.

But that demonstrates the real problem here, right? Every time the company makes a sale, it loses revenue, cash flow, and potential earnings. And with so much debt on the horizon, how can Valeant possibly hope to pay debt if divisions are continuously sold? It becomes a race between the total debt and how much selling can occur.

Ideally, the company will find success with its pipeline to make up for these sales.

One option is the psoriasis drug Siliq, which is just beginning to ramp up. Analysts at Credit Suisse suggested this could be a US$600-million-a-year business for Valeant at full ramp-up.

An analyst from Wells Fargo, though, suggested that it might only be US$250 million. It is shown to be more effective than other competitors, but the marketing dollars that others are putting toward their products far surpass what Valeant is investing.

All told, the company expects to see over US$100 million in revenue thanks to these new product launches. That’s going to be important, and I hope that 2018 and 2019 will bring even greater launches. If not, the debt will become a problem again.

If you want to buy, that’s not a bad idea. Just understand that you’re buying with a long-term mentality and that the investment thesis could wind up exploding on you.

Just Released! 5 Stocks Under $50 (FREE REPORT)

Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $50 a share.

Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.

Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.

Claim your FREE 5-stock report now!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in the companies mention. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

clock time
Bank Stocks

1 Magnificent Financial Stock Down 23% to Buy and Hold Forever

This top TSX financial stock is trading well below its recent peak, but its long-term fundamentals remain rock solid.

Read more »

dividend growth for passive income
Bank Stocks

This Canadian Bank Pays 4.75% and Could Double Your Money by 2030

A Canadian bank is a top pick for its lucrative dividend and potential to double your money in five years.

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Dividend Stocks

How I’d Invest $7,000 in My TFSA for $660 in Tax-Free Annual Income

Canadians looking for ways to make the most of the new TFSA contribution room should consider investing in these two…

Read more »

oil and natural gas
Energy Stocks

1 Magnificent Canadian Energy Stock Down 23% to Buy and Hold for Decades

This oil and gas producer has increased its dividend annually for more than two decades.

Read more »

Silhouette of bull in front of setting sun
Investing

Where I’d Invest $2,500 in the TSX Today

Given their solid underlying businesses and healthy growth prospects, I am bullish on these TSX stocks.

Read more »

path road success business
Dividend Stocks

How to Invest $50,000 of Tax-Free Cash as Canada-US Trade Uncertainty Escalates

Few Canadian stocks are as easy a choice as this one, making it perfect during volatile periods.

Read more »

Doctor talking to a patient in the corridor of a hospital.
Dividend Stocks

This Dividend King Paying 7.5% in Monthly Income Is a Must-Have

This high-yield TSX stock might not be a textbook Dividend King, but its reliable monthly payouts and improving financials make…

Read more »

monthly desk calendar
Dividend Stocks

How I’d Generate $200 in Monthly Income With a $7,000 Investment

Want to establish $200 in monthly income (or even more?) Here's an easy way to start today that will provide…

Read more »